Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 3, 2010, Pages 332-340

  De Castro, L ^a   Do Brasil, P E A A ^a   Monteiro, T P ^a   Rolla, V C ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Anti tuberculosis agents; Drug toxicity; Hepatitis B; HIV; Nomograms; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; BILIRUBIN; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; MEMBRANE ANTIGEN; NELFINAVIR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; DRUG WITHDRAWAL; ETHNICITY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SURVIVAL; TOBACCO DEPENDENCE; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CONTINENTAL POPULATION GROUPS; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEXUAL PARTNERS; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 77949521781     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Maddrey W C. Hepatitis B - an important public health issue. Clin Lab 2001; 47: 51-55.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/publications/global-report/2008/pdf/fullreport. pdf Accessed November 2009.
3. Blal C A, Passos S R L, Horn C, et al. High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil. Eur J Clin Microbiol Infect Dis 2005; 24: 41-43.
4. Palella F J, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
5. Tseng S, Jiang D D, Hoi H, Yang S, Hwang K. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan. Am J Trop Med Hyg 2009; 80: 675-677.
6. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007; 21: 2521-2527.
7. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2007; 2: e826.
8. Santoro-Lopes G, de Pinho A M F, Harrison H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546.
9. Breen R A M, Swaden L, Ballinger J, Lipman M C I. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006; 66: 2299-2308.
10. Wong W M, Wu P C, Yuen M F, et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
11. Pan L, Jia Z, Chen L, Fu E, Li G. Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 2005; 11: 2518-2521.
12. Hoffmann C J, Charalambous S, Thio C L, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21: 1301-1308.
13. Patel P A, Voigt M D. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97: 1198-1203.
14. Sulkowski M S, Thomas D L, Mehta S H, Chaisson R E, Moore R D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
15. Masur J, Monteiro M G. Validation of the CAGE alcoholism screening test in a Brazilian psychiatric inpatient hospital setting. Braz J Med Biol Res 1983; 6: 15-18.
16. Rothman K J, Greenland S, eds. Modern epidemiology. 3rd ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 1998.
17. Pan W, Chappell R. A Nonparametric estimator of survival functions for arbitrarily truncated and censored data. Lifetime Data Anal 1998; 4: 187-202.
18. Lubsen J, Pool J, van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med 1978; 17: 127-129.
19. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: Department of Statistics and Mathematics, WU Wien, 2009. http://cran.r-project.org/doc/manuals/refman.pdf Accessed November 2009.
20. Zago A M, Machado T F, Cazarim F L, Miranda A E. Prevalence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitória, Brazil. Braz J Infect Dis 2007; 11: 475-478.
21. Tovo C V, Dos Santos D E, de Mattos A Z, et al. [Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital]. Arq Gastroenterol 43: 73-76. [Portuguese]
22. Miranda A E, Figueiredo N C, Schmidt R, Page-Shafer K. A population-based survey of the prevalence of HIV, syphilis, hepatitis B and hepatitis C infections, and associated risk factors among young women in Vitória, Brazil. AIDS Behav 2008; 12 (Suppl): S25-S31.
23. de Almeida Pereira R A R, Mussi A D H, de Azevedo e Silva V C, Souto F J D. Hepatitis B virus infection in HIV-positive population in Brazil: results of a survey in the state of Mato Grosso and a comparative analysis with other regions of Brazil. BMC Infect Dis 2006; 6: 34.
24. Braga W S M, da Costa Castilho M, dos Santos I C V, Moura M A S, Segurado A C. Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among patients with human immunodeficiency virus or acquired immunodeficiency syndrome in the Brazilian Amazon basin. Rev Soc Bras Med Trop 39: 519-522.
25. Monteiro M R D C C, do Nascimento M M P, Passos A D C, Figueiredo J F D C. [Soroepidemiological survey of hepatitis B virus among HIV/AIDS patients in Belém, Pará, Brasil]. Rev Soc Bras Med Trop 2004; 37 (Suppl 2): S27-S32. [Portuguese]
26. Souza M G D, Passos A D C, Machado A A, Figueiredo J F D C, Esmeraldino L E. [HIV and hepatitis B virus co-infection: prevalence and risk factors]. Rev Soc Bras Med Trop 2004; 37: 391-395. [Portuguese]
27. Tostmann A, Boeree M, Aarnoutse R, et al. Anti-tuberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
28. Yew W, Leung C. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
29. Possuelo L, Castelan J, De Brito T, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64: 673-681.
30. Hoffmann C J, Charalambous S, Martin D J, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47: 1479-1485.
31. Steyerberg E W. Clinical prediction models: a practical approach to development, validation, and updating. 1st ed. New York, NY, USA: Springer, 2008.